Article Text

PDF
SAT0366 Effect of First-Line Anti-TNF Therapy on Fatigue in Patients with Ankylosing Spondylitis – Results from the Czech BIOLOGICS Registry Attra
  1. S. Forejtova1,
  2. K. Jarosova1,
  3. M. Votavova1,
  4. M. Uher2,
  5. K. Hejduk3,
  6. K. Pavelka1
  1. 1Institute of Rheumatology, Prague
  2. 2Institute of Biostatistics and Analysis, Masaryk University
  3. 3Institut of Biostatistics and Analysis, Masaryk University, Brno, Czech Republic

Abstract

Objectives The aim of this study was to describe the influence of anti-TNF therapy on the fatigue in patients with ankylosing spondylitis (AS) and compare the results with the influence of the therapy on the disease activity

Methods We used Vitality score (subscale from SF-36) for the assessment of fatigue and BASDAI for the evaluation of the disease activity. Values of Vitality score, BASDAI and their improvements were described using median and interquartile range (IQR). Statistical significance of differences between 3-month visit and treatment initiation and between one-year visit and 3-month visit were assessed using Wilcoxon Signed Ranks Test. Kruskal-Wallis H test was used to assess differences between gender and age categories (while level of significance α =0.05).

Results 588 AS patients [mean age of 37,6 years (standard deviation 10,5) and mean disease duration of 8 years (standard deviation 7,4) at the start of anti-TNF treatment]were included in the analyses. Men assessed Vitality at the start of treatment better than women (p=0.003), but there was no difference in improvement in Vitality after therapy between the sexes. Compare to patients aged >50 years, there was more improvement in BASDAI assessment in patients aged <30 years (p=0.002) and also in group aged 30-39 (p=0.020) after 3 months of therapy, but there were no statistical differences between various age groups in the improvement of Vitality score after 3 and 12 months of therapy.

Conclusions Based on subanalysis of age groups there were significant improvements in fatigue and disease activity after 3 months and also significant improvement in disease activity between 12 and 3 months within all age groups, but interestingly there was no significant improvement in fatigue between 12 and 3 months within all age groups besides group of patients aged 30-39 years.

Acknowledgements Supported by project 00023728 from Ministry of Health in the Czech Republic.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3184

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.